JP2012105650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012105650A5 JP2012105650A5 JP2011277848A JP2011277848A JP2012105650A5 JP 2012105650 A5 JP2012105650 A5 JP 2012105650A5 JP 2011277848 A JP2011277848 A JP 2011277848A JP 2011277848 A JP2011277848 A JP 2011277848A JP 2012105650 A5 JP2012105650 A5 JP 2012105650A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- substitution
- amino acid
- a3ay
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 29
- 102220494690 Small vasohibin-binding protein_K32E_mutation Human genes 0.000 claims 18
- 102220494687 Small vasohibin-binding protein_R36E_mutation Human genes 0.000 claims 17
- 230000037431 insertion Effects 0.000 claims 11
- 238000003780 insertion Methods 0.000 claims 11
- 102220595361 Anamorsin_A34E_mutation Human genes 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000034158 bleeding Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000004988 N-glycosylation Effects 0.000 claims 3
- 108010054265 Factor VIIa Proteins 0.000 claims 2
- 108010014173 Factor X Proteins 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 229940012414 factor viia Drugs 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 229940099816 human factor vii Drugs 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47978003P | 2003-06-19 | 2003-06-19 | |
| US60/479,780 | 2003-06-19 | ||
| DKPA200400930 | 2004-06-15 | ||
| DKPA200400930 | 2004-06-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Division JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012105650A JP2012105650A (ja) | 2012-06-07 |
| JP2012105650A5 true JP2012105650A5 (enExample) | 2013-03-07 |
| JP5580283B2 JP5580283B2 (ja) | 2014-08-27 |
Family
ID=33553697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Expired - Fee Related JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
| JP2011277848A Expired - Fee Related JP5580283B2 (ja) | 2003-06-19 | 2011-12-20 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Expired - Fee Related JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20050164932A1 (enExample) |
| EP (1) | EP1644504B8 (enExample) |
| JP (2) | JP4915918B2 (enExample) |
| KR (1) | KR101191779B1 (enExample) |
| CN (1) | CN1839203B (enExample) |
| AT (1) | ATE458057T1 (enExample) |
| AU (2) | AU2004247799B2 (enExample) |
| BR (1) | BRPI0411650A (enExample) |
| CA (1) | CA2529828C (enExample) |
| CY (1) | CY1109984T1 (enExample) |
| DE (1) | DE602004025576D1 (enExample) |
| DK (1) | DK1644504T3 (enExample) |
| ES (1) | ES2338425T3 (enExample) |
| HR (1) | HRP20100264T1 (enExample) |
| IL (1) | IL172364A (enExample) |
| MX (1) | MXPA05013769A (enExample) |
| NZ (2) | NZ573412A (enExample) |
| PL (1) | PL1644504T3 (enExample) |
| PT (1) | PT1644504E (enExample) |
| RU (1) | RU2373282C2 (enExample) |
| SI (1) | SI1644504T1 (enExample) |
| WO (1) | WO2004111242A1 (enExample) |
| ZA (1) | ZA200600539B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2739933A1 (en) | 2000-02-11 | 2001-08-16 | Bayer Healthcare Llc | Factor vii or viia-like molecules |
| WO2003093465A1 (en) * | 2002-04-30 | 2003-11-13 | Maxygen Holdings Ltd. | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
| CA2519873C (en) | 2003-03-20 | 2012-12-18 | Maxygen Holdings Ltd. | Fvii or fviia variants |
| RU2373282C2 (ru) * | 2003-06-19 | 2009-11-20 | Байер Хелткэр Ллк | ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa |
| WO2006018204A1 (en) | 2004-08-17 | 2006-02-23 | Zlb Behring Gmbh | Modified vitamin k dependent polypeptides |
| WO2006114105A2 (en) * | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| WO2007006808A1 (en) | 2005-07-13 | 2007-01-18 | Novo Nordisk Health Care Ag | Host cell protein knock-out cells for production of therapeutic proteins |
| US20070129298A1 (en) * | 2005-07-22 | 2007-06-07 | Maxygen Holdings, Ltd. | In-solution activation of factor vii |
| JP5894722B2 (ja) | 2005-09-01 | 2016-03-30 | ノボ ノルディスク ヘルス ケア アーゲー | 第ｖｉｉ因子ポリペプチドの疎水性相互作用クロマトグラフィ精製 |
| JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| EP2423307A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IV polypeptides and use thereof for treatment |
| WO2008025856A2 (en) | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Modified glycoproteins |
| FR2910969B1 (fr) * | 2006-12-29 | 2009-02-27 | Lab Francais Du Fractionnement | Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon |
| EP1952822A1 (en) * | 2007-01-26 | 2008-08-06 | Novo Nordisk A/S | Factor VII polypeptides with increased affinity to platelets |
| CA2683443A1 (en) | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides and uses thereof |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| WO2010149172A2 (en) | 2009-06-24 | 2010-12-29 | Rigshospitalet | SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. |
| FR2947181B1 (fr) * | 2009-06-26 | 2012-05-04 | Lfb Biotechnologies | Composition de facteur vii |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| BR112015015182B1 (pt) * | 2012-12-24 | 2023-12-26 | Coagulant Therapeutics Corporation | Variante polipeptídica isolada do fator vii, seu método de preparação e seu uso, e composições farmacêuticas e seus usos |
| BR112015021866A2 (pt) | 2013-03-15 | 2017-08-29 | Bayer Healthcare Llc | Domínios de gla como agentes direcionadores |
| CN104211802B (zh) * | 2013-05-29 | 2018-07-27 | 成都渊源生物科技有限公司 | 人凝血因子轻链蛋白及其应用 |
| EP3230309B1 (en) | 2014-12-10 | 2023-03-29 | OPKO Biologics Ltd. | Methods of producing long acting ctp-modified growth hormone polypeptides |
| EP3442554A4 (en) * | 2016-04-14 | 2019-12-04 | Iconic Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION |
| MY206271A (en) | 2016-07-11 | 2024-12-06 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
| EP3679129A1 (en) | 2017-09-05 | 2020-07-15 | GLAdiator Biosciences, Inc. | A method of intracellular delivery |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA862768B (en) * | 1985-04-17 | 1986-12-30 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| EP0296413A2 (en) | 1987-06-12 | 1988-12-28 | Hoechst Japan Limited | Hybrid protein C and method for its preparation |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| JPH0246296A (ja) | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US5041376A (en) * | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5225537A (en) * | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
| DE69101634T4 (de) | 1990-01-26 | 1994-12-01 | Immuno Ag | Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus. |
| ATE180834T1 (de) * | 1990-01-29 | 1999-06-15 | Zymogenetics Inc | Antikoagulierende proteine |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5531916A (en) * | 1990-10-03 | 1996-07-02 | E. I. Du Pont De Nemours And Company | Hydrofluorocarbon cleaning compositions |
| ATE158816T1 (de) * | 1990-11-26 | 1997-10-15 | Genetics Inst | Expression von pace in wirtszellen und verfahren zu dessen verwendung |
| US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| WO1992015686A1 (en) | 1991-02-28 | 1992-09-17 | Zymogenetics, Inc. | Modified factor vii |
| US5833982A (en) * | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| JPH0720127A (ja) * | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種ｐｉｖｋａの測定方法および測定試薬 |
| EP0699075B1 (en) | 1993-05-21 | 2001-12-12 | Zymogenetics, Inc. | MODIFIED FACTOR VII for inhibiting vascular restenosis and platelet deposition |
| DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
| CA2271232C (en) * | 1996-11-08 | 2005-02-22 | Oklahoma Medical Research Foundation | Modified protein c and methods of use thereof |
| US5837843A (en) * | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
| WO1998032466A1 (en) | 1997-01-29 | 1998-07-30 | Polymasc Pharmaceuticals Plc | Pegylation process |
| JP2001511162A (ja) | 1997-02-06 | 2001-08-07 | ノボ ノルディスク アクティーゼルスカブ | 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体 |
| US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| ES2339196T3 (es) | 1997-07-18 | 2010-05-17 | Novo Nordisk Health Care Ag | Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente. |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| ES2220114T3 (es) | 1998-10-30 | 2004-12-01 | Novozymes A/S | Variantes de proteinas poco alergenicas. |
| ATE365210T1 (de) | 1998-10-30 | 2007-07-15 | Novozymes As | Glykosylierte proteine mit reduzierter allergenität |
| ES2315022T3 (es) | 1998-11-06 | 2009-03-16 | Novo Nordisk Health Care Ag | Metodo para la produccion de fvii. |
| WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| CA2739933A1 (en) * | 2000-02-11 | 2001-08-16 | Bayer Healthcare Llc | Factor vii or viia-like molecules |
| US7220837B1 (en) * | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| JP4455802B2 (ja) | 2000-05-03 | 2010-04-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト第ｖｉｉ凝固因子変異型 |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| WO2002022776A2 (en) | 2000-09-13 | 2002-03-21 | Novo Nordisk A/S | Human coagulation factor vii variants |
| MXPA03001984A (es) * | 2000-09-13 | 2003-08-29 | Novo Nordisk Healthcare Ag | Variantes de factor vii de coagulacion humano. |
| BR0114373A (pt) | 2000-10-02 | 2004-02-17 | Novo Nordisk As | Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante |
| WO2002038162A1 (en) | 2000-11-09 | 2002-05-16 | The Scripps Research Institute | MODIFIED FACTOR VIIa |
| CZ20032454A3 (en) | 2001-03-22 | 2004-03-17 | Novo Nordisk Health Care Ag | Coagulation factor vii derivative |
| CZ2004427A3 (cs) | 2001-09-27 | 2004-08-18 | Novoánordiskáhealthácareáag | Polypeptidy lidského koagulačního faktoru VII |
| JP2005512524A (ja) | 2001-11-02 | 2005-05-12 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固第ｖｉｉ因子ポリペプチド |
| EP1458408B1 (en) | 2001-12-21 | 2009-04-15 | Novo Nordisk Health Care AG | Liquid composition of factor vii polypeptides |
| WO2003093465A1 (en) * | 2002-04-30 | 2003-11-13 | Maxygen Holdings Ltd. | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
| CA2840692A1 (en) * | 2002-09-30 | 2004-04-08 | Bayer Healthcare Llc | Fvii or fviia variants having increased clotting activity |
| CA2519873C (en) * | 2003-03-20 | 2012-12-18 | Maxygen Holdings Ltd. | Fvii or fviia variants |
| US20060116324A1 (en) * | 2003-06-13 | 2006-06-01 | Novo Nordisk Healthcare A/G | Novel formulations |
| RU2373282C2 (ru) * | 2003-06-19 | 2009-11-20 | Байер Хелткэр Ллк | ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa |
-
2004
- 2004-06-18 RU RU2006101391/13A patent/RU2373282C2/ru not_active IP Right Cessation
- 2004-06-18 DE DE602004025576T patent/DE602004025576D1/de not_active Expired - Lifetime
- 2004-06-18 NZ NZ573412A patent/NZ573412A/en not_active IP Right Cessation
- 2004-06-18 PL PL04738925T patent/PL1644504T3/pl unknown
- 2004-06-18 DK DK04738925.9T patent/DK1644504T3/da active
- 2004-06-18 AT AT04738925T patent/ATE458057T1/de active
- 2004-06-18 EP EP04738925A patent/EP1644504B8/en not_active Expired - Lifetime
- 2004-06-18 MX MXPA05013769A patent/MXPA05013769A/es active IP Right Grant
- 2004-06-18 SI SI200431396T patent/SI1644504T1/sl unknown
- 2004-06-18 KR KR1020057024386A patent/KR101191779B1/ko not_active Expired - Fee Related
- 2004-06-18 HR HR20100264T patent/HRP20100264T1/hr unknown
- 2004-06-18 ES ES04738925T patent/ES2338425T3/es not_active Expired - Lifetime
- 2004-06-18 AU AU2004247799A patent/AU2004247799B2/en not_active Ceased
- 2004-06-18 CN CN2004800237774A patent/CN1839203B/zh not_active Expired - Fee Related
- 2004-06-18 NZ NZ544728A patent/NZ544728A/en unknown
- 2004-06-18 BR BRPI0411650-0A patent/BRPI0411650A/pt not_active IP Right Cessation
- 2004-06-18 JP JP2006515723A patent/JP4915918B2/ja not_active Expired - Fee Related
- 2004-06-18 PT PT04738925T patent/PT1644504E/pt unknown
- 2004-06-18 WO PCT/DK2004/000428 patent/WO2004111242A1/en not_active Ceased
- 2004-06-18 CA CA2529828A patent/CA2529828C/en not_active Expired - Fee Related
- 2004-12-22 US US11/021,239 patent/US20050164932A1/en not_active Abandoned
-
2005
- 2005-12-05 IL IL172364A patent/IL172364A/en not_active IP Right Cessation
-
2006
- 2006-01-19 ZA ZA2006/00539A patent/ZA200600539B/en unknown
- 2006-04-21 US US11/379,664 patent/US20060252128A1/en not_active Abandoned
- 2006-06-14 US US11/424,035 patent/US8987202B2/en not_active Expired - Fee Related
- 2006-06-14 US US11/424,030 patent/US7807638B2/en not_active Expired - Fee Related
- 2006-12-21 US US11/643,535 patent/US20070117756A1/en not_active Abandoned
-
2010
- 2010-03-02 AU AU2010200793A patent/AU2010200793B2/en not_active Ceased
- 2010-04-23 CY CY20101100374T patent/CY1109984T1/el unknown
-
2011
- 2011-12-20 JP JP2011277848A patent/JP5580283B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012105650A5 (enExample) | ||
| JP2006527982A5 (enExample) | ||
| JP2012095641A5 (enExample) | ||
| RU2004134726A (ru) | Варианты полипептида фактора vii или viia | |
| JP2006521098A5 (enExample) | ||
| JP2005270110A5 (enExample) | ||
| HRP20100264T1 (hr) | Varijante gla domene faktora vii ili viia | |
| RU2002124129A (ru) | Молекулы, подобные фактору vii или viia | |
| CA2519873A1 (en) | Fvii or fviia variants | |
| CN101557830B (zh) | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 | |
| JP2006517089A5 (enExample) | ||
| JP2014113157A5 (enExample) | ||
| JP2014513952A5 (enExample) | ||
| TW200942258A (en) | Factor VII polypeptides that are modified and uses thereof | |
| BRPI0513143A (pt) | antagonistas de vla-4 multivalentes compreendendo porções poliméricas | |
| AU2013219935B2 (en) | Long-acting coagulation factors and methods of producing same | |
| WO2006108718B1 (en) | Micro rna | |
| JP2012176978A5 (enExample) | ||
| JP2015521589A (ja) | プロコアグラント化合物 | |
| JP2013163674A5 (enExample) | ||
| JP2010530238A5 (enExample) | ||
| JP2010513327A5 (enExample) | ||
| KR20180030542A (ko) | 장기-작용성 응고 인자 및 그의 제조 방법 | |
| JP2016540739A (ja) | 神経保護ペプチド | |
| RU2010144014A (ru) | Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств |